Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
February 29 2024 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global
pharmaceutical company whose mission is to be invaluable to
patients, physicians and partners concerned with retinal health and
maintaining better vision longer, announces today that it will
report fourth quarter and full year 2023 financial results on March
7, 2024, prior to the market open.
Management will host a conference call at 9:00 AM ET on the same
day, to review financial results and provide an update on corporate
developments. Following management’s formal remarks there will be a
question-and-answer session.
Participants can register for the conference by navigating to
https://dpregister.com/sreg/10186495/fb9ad32c9b
Please note that registered participants will receive their
dial-in number upon registration and will dial directly into the
call without delay. Those without Internet access or who are unable
to pre-register may dial in by calling 1-844-839-2190 (domestic) or
1-412-717-9583 (international). All callers should dial in
approximately 10 minutes prior to the scheduled start time and ask
to be joined into the Alimera Sciences call.
The conference call will also be available through live webcast
at https://event.choruscall.com/mediaframe/webcast.html?webcastid=MezI6DhP
and is also available through the company’s website.
A webcast replay of the call will be available approximately one
hour after the end of the call through June 7, 2024. The webcast
replay can be accessed through the above links or by calling
1-877-344-7529 (domestic) or 1-412-317-0088 (toll) or via an
international dial-in number at:
https://services.choruscall.com/ccforms/replay.html. Please use the
following replay code 3648198. The telephonic replay will be
available until March 21, 2024.
About Alimera Sciences, Inc.Alimera Sciences is
a global pharmaceutical company whose mission is to be invaluable
to patients, physicians and partners concerned with retinal health
and maintaining better vision longer. For more information, please
visit www.alimerasciences.com.
For press inquiries:Jules Abrahamfor Alimera
Sciences917-885-7378julesa@coreir.com |
For investor inquiries:Scott Gordonfor Alimera
Sciencesscottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Jul 2023 to Jul 2024